Preventive effects of pneumococcal and influenza vaccines on community-acquired pneumonia in older individuals in Japan: a case-control study

References

• Health, labour and welfare statistics association. Annual statistical report of national health conditions. Journal of health and welfare statistics. 2014;61:49–82 [in Japanese].
   Google Scholar
• Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. Vaccine. 1999;17:S91–3. doi:10.1016/S0264-410X(99)00114-0.
   PubMed Web of Science ®Google Scholar
• Hedlund J, Christenson B, Lundbergh P, Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines elderly in elderly people: a 1-year follow-up. Vaccine. 2003;21:3906–11. doi:10.1016/S0264-410X(03)00296-2.
   PubMed Web of Science ®Google Scholar
• Christenson B, Hedlund J, Lundbergh P, Ortqvist A. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J. 2004;23:363–68. doi:10.1183/09031936.04.00063504.
   PubMed Web of Science ®Google Scholar
• Hung IFN, Leung AYM, Chu DWS, Leung D, Cheung T, Chan CK, Lam CLK, Liu S-H, Chu C-M, Ho P-L, et al. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: A prospective cohort study. CID. 2010;51:1007–16. doi:10.1086/656587.
   PubMed Web of Science ®Google Scholar
• Chang YC, Chou YJ, Liu JY, Yeh TF, Huang N. Additive benefits of pneumococcal and influenza vaccines among elderly persons aged 75 years or older in Taiwan — A representative population-based comparative study. J Infect. 2012;65:231–38. doi:10.1016/j.jinf.2012.04.014.
   PubMed Web of Science ®Google Scholar
• Li C, Gubbins PO, Chen GJ. Prior pneumococcal and influenza vaccinations and in-hospital outcomes for community-acquired pneumonia in elderly veterans. J Hosp Med. 2015;10:287–93. doi:10.1002/jhm.2328.
   PubMed Web of Science ®Google Scholar
• Maruyama T, Taguchi O, Niederman MS, Morser J, Kobayashi H, Kobayashi T, D’Alessandro-Gabazza C, Nakayama S, Nishikubo K, Noguchi T, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomized and placebo controlled trial. BMJ. 2010;340:c1004. doi:10.1136/bmj.c1004.
   PubMed Web of Science ®Google Scholar
• Kawakami K, Ohkusa Y, Kuroki R, Tanaka T, Koyama K, Harada Y, Iwanaga K, Ymaryo T, Oishi K. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine. 2010;28:7063–69. doi:10.1016/j.vaccine.2010.08.010.
   PubMed Web of Science ®Google Scholar
• Kondo K, Suzuki K, Washio M, Ohfuji S, Fukushima W, Maeda A, Hirota Y. Effectiveness of 23-valent pneumococcal polysaccharide vaccine and seasonal influenza vaccine for pneumonia among the elderly –selection of controls in a case-control study. Vaccine. 2017;35:4806–10. doi:10.1016/j.vaccine.2017.07.005.
   PubMed Web of Science ®Google Scholar
• The Japanese respiratory society. The JRS guidelines 2017 for the management of pneumonia in adults. Tokyo:NPC; 2017. p.155–158 [in Japanese].
   Google Scholar
• Hoshi SL, Kondo M, Okubo I. Pricing and uptake rate of public funded pneumococcal vaccination for the elderly in Japan. Nihon Koshu Eisei Zasshi. 2010;57(7):505–13. [in Japanese].
   PubMedGoogle Scholar
• Pneumococcal infection (elderly person). Ministry of health, labour and welfare. http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/kekkaku-kansenshou/haienkyukin/index_1.html [accessed 18 November 2018].
   Google Scholar
• Naito T, Matsuda N, Tanei M, Watanabe Y, Watanabe A. Relationship between public subsidies and vaccination rates with the 23-valent pneumococcal vaccine in elderly persons, including the influence of the free vaccination campaign after the Great East Japan Earthquake. J Infect Chemother. 2014;20:450–53. doi:10.1016/j.jiac.2014.03.004.
   PubMed Web of Science ®Google Scholar
• The number of the periodical vaccination enforcers. Ministry of health, labour and welfare. https://www.mhlw.go.jp/topics/bcg/other/5.html [accessed 24 October 2018].
   Google Scholar
• Tin Tin Htar M, Stuurman AL, Ferreira G, Alicino C, Bollaerts K, Paganino C, Reinert RR, Schmitt H-J, Trucchi C, Vestraeten T, et al. Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies. PLoS One. 2017;12(5):e0177985. doi:10.1371/journal.pone.0177985.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Dhoubhadel BG, Ishifuji T, Yasunami M, Yaegashi M, Asoh N, Ishida M, Hamaguchi S, Aoshima M, Ariyoshi K, et al. Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. Lancet Infect Dis. 2017;17:313–21. doi:10.1016/S1473-3099(17)30049-X.
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Ochoa-Gondar O, Hospital I, Ansa X, Vilanova A, Rodriguez T, Llor C. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly: the EVAN-65 study. CID. 2006;43:860–68. doi:10.1086/507340.
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Salsench E, Rodriguez-Blanco T, Ochoa-Gondar O, de Diego C, Valdivieso A, Hospital I, Gomez-Bertomeu F, Raga X. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vaccine. 2009;27:1504–10. doi:10.1016/j.vaccine.2009.01.013.
   PubMed Web of Science ®Google Scholar
• Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, Gomez-Bertomeu F, Figuerola-Massana E, Raga-Luria X, Hospital-Guardiola I. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥60 years: 3 years of follow-up in the CAPAMIS study. CID. 2014;58:909–17. doi:10.1093/cid/ciu002.
   PubMed Web of Science ®Google Scholar
• Ubukata K, Chiba N, Hanada S, Morozumi M, Wajima T, Shouji M, Iwata S. Serotype changes and drug resistance in invasive pneumococcal diseases in adults after vaccinations in children, Japan, 2010-2013. Emerg Infect Dis. 2015;21:1956–65. doi:10.3201/eid2111.142029.
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32–41. doi:10.1086/648593.
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Petit S, Zansky SM, Harrison LH, Reingold A, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15:301–09. doi:10.1016/S1473-3099(14)71081-3.
   PubMed Web of Science ®Google Scholar
• Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, Levine OS, Whitney CG, O’Brien KL, Moore MR. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013;10:e1001517. doi:10.1371/journal.pmed.1001517.
   PubMed Web of Science ®Google Scholar
• Morimoto K, Suzuki M, Ishifuji T, Yaegashi M, Asoh N, Hamashige N, Abe M, Aoshima M, Ariyoshi K. The burden and etiology of community-onset pneumonia in the aging Japanese population: a multicenter prospective study. PLoS One. 2015;10:e0122247. doi:10.1371/journal.pone.0122247.
   PubMed Web of Science ®Google Scholar
• Teramoto S, Fukuchi Y, Sasaki H, Sato K, Sekizawa K, Matsuse T. Japanese Study Group on Aspiration Pulmonary Disease. High incidence of aspiration pneumonia in community- and hospital-acquired pneumonia in hospitalized patients: a multicenter, prospective study in Japan. J Am Geriatr Soc. 2008;56(3):577–79. doi:10.1111/j.1532-5415.2008.01597.x.
   PubMed Web of Science ®Google Scholar
• Ishiguro T, Takayanagi N, Yamaguchi S, Yamakawa H, Nakamoto K, Takaku Y, Miyahara Y, Kagiyama N, Kurashima K, Yanagisawa T, et al. Etiology and factors contributing to the severity and mortality of community-acquired pneumonia. Intern Med. 2013;52:317–24. doi:10.2169/internationalmedicine.52.8830.
   PubMed Web of Science ®Google Scholar
• Washio M, Kondo K, Fujisawa N, Harada E, Tashiro H, Mizokami T, Nogami H, Iwanaga T, Nakanishi Y, Suzuki K, et al. Hypoalbuminemia, influenza vaccination and other factors related to the development of pneumonia acquired outside hospitals in southern Japan: A case–control study. Geriatr Gerontol Int. 2016;16:223–29. doi:10.1111/ggi.12456.
   PubMed Web of Science ®Google Scholar
• Govaert ThME, Thijs CTMCN, Masurel N, Sprenger MJW, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccine in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA. 1994;272:1661–65. doi:10.1001/jama.1994.03520210045030.
   PubMed Web of Science ®Google Scholar
• Hirota Y, Fukushima W, Fujieda M, Ohfuji S, Maeda A. Essential tools for assessing influenza vaccine efficacy in improperly conducted studies: a Japanese perspective. Vaccine. 2008;26:6455–58. doi:10.1016/j.vaccine.2008.06.041.
   PubMed Web of Science ®Google Scholar
• Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine. 2013;31:2165–68. doi:10.1016/j.vaccine.2013.02.053.
   PubMed Web of Science ®Google Scholar
• Sullivan SG, Tay EL, Kelly H. Variable definitions of the influenza season and their impact on vaccine effectiveness estimates. Vaccine. 2013;31:4280–83. doi:10.1016/j.vaccine.2013.06.103.
   PubMed Web of Science ®Google Scholar
• Mufson MA, Krause HE, Schiffman G. Long-term persistence of antibody following immunization with pneumococcal polysaccharide vaccine. Proc Soc Exp Biol Med. 1983;173:270–75. doi:10.3181/00379727-173-41643.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1997;46(RR–8):1–24.
   PubMedGoogle Scholar
• Sumitani M, Tochino Y, Kamimori T, Fujiwara H, Fujikawa T. Additive inoculation of influenza vaccine and 23-valent pneumococcal polysaccharide vaccine to prevent lower respiratory tract infections in chronic respiratory disease patients. Intern Med. 2008;47:1189–97. doi:10.2169/internationalmedicine.47.0799.
   PubMed Web of Science ®Google Scholar
• Kondo K, Suzuki K, Washio M, Ohfuji S, Fukushima W, Maeda A, Hirota Y. Association between monovalent influenza A (H1N1) pdm09 vaccine and pneumonia among the elderly in the 2009–2010 season in Japan: a case-control study. Hum Vaccin Immunother. 2015;11:1088–93. doi:10.1080/21645515.2015.1016668.
   PubMed Web of Science ®Google Scholar
• Ohfuji S, Okada K, Nakano T, Ito H, Hara M, Kuroki H, Hirota Y. Effectiveness of acellular pertussis vaccine in a routine immunization program: A multicenter, case-control study in Japan. Vaccine. 2015;33:1027–32. doi:10.1016/j.vaccine.2015.01.008.
   PubMed Web of Science ®Google Scholar